14 vs 24 weeks HCV [hepatitis C virus] treatment to genotype 2/3 patients with rapid virological response.

Trial Profile

14 vs 24 weeks HCV [hepatitis C virus] treatment to genotype 2/3 patients with rapid virological response.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2011

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms NORTH-C
  • Most Recent Events

    • 24 May 2007 Status change
    • 14 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top